A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-05-19
Adverse events
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-26 (study day 86); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-21 (study day 173); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-04 (study day 248); relationship: not assessed
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 254); relationship: N
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 309); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-10 (study day 313); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-02 (study day 335); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-06-03 (study day 733); relationship: not assessed
Data queries
No data queries.